MedTrace Logo

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

NCT02240667 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1506

Last updated 2019-04-19

Study results available
· View outcomes & findings →

Summary

1600 AF patients receiving Pradaxa or VKA for stroke prevention will be followed up for 12 months in quarterly visits. Prescriptions, adverse events and (if applicable) reasons for definitive treatment discontinuation will be collected. At 6 months, patient adherence will be assessed, using the Morisky Score.

Conditions

Interventions

DRUG

Dabigatran etexilate

150 mg or 110 mg capsules twice daily

DRUG

Vitamin K antagonists

International Normalized Ratio (INR) 2-3

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-18
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • Germany

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02240667 on ClinicalTrials.gov